A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 801–900 of 1,002
Ziff, O. J., Jolly, S., Casey, J. M., Granat, L., Samra, S., Setó‐Salvia, N., Alatza, A., Phadke, L., Galet, B., Ravassard, P., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00864-7 · Cited by 10
“These findings are relevant to translational efforts, including ongoing γ-secretase modulator trials and the unsuccessful clinical trials of γ-secretase inhibitors, which worsened disease-associated phenotypes concomitant with increased infections rates [72].”
Functional nanomaterial strategies for targeted CNS drug delivery
Ye, R., Zhang, Y., Jiao, X., Xu, W. X., Chen, Y., Nai, L., Guo, Q., Wang, J., Zhao, Z., Liu, S., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907836 · Cited by 11
Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease
Espay, A. J., Ezzat, K., Kepp, K. P., Daly, T. P., Robakis, N. K. R. K., Meijer, L., & Imbimbo, B. P. (2025) · Brain · doi:10.1093/brain/awaf294 · Cited by 10
Fujikawa, R., Higuchi, S., Nakatsuji, M., Yasui, M., Ikedo, T., Nagata, M., Hayashi, K., Yokode, M., & Minami, M. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.010 · Cited by 10
Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them
Espay, A. J., & Stecher, B. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108888202 · Cited by 10
Arora, A., Nain, P., Kumari, R., & Kaur, J. (2021) · Archives of Pharmacy Practice · doi:10.51847/yjqdk2wtgx · Cited by 12
Isla, A. G., Balleza‐Tapia, H., Chu, F., Chen, G., Johansson, J., Nilsson, P., & Fisahn, A. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114545 · Cited by 11
“…A β load per se is not enough to recover cognitive function: One dramatic case is semagacestat, a gamma-secretase inhibitor that not only failed during phase 3 to improve the memory outcome in AD patients but even worsens the alterations despite a reduction of A β load (Doody et al., 2013).”
BackgroundHakem, F. T., Fouad, Y. F., & Arafa, R. K. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266259174231006070637 · Cited by 12
Folates Induce Colorectal Carcinoma HT29 Cell Line Proliferation Through Notch1 Signaling
Rodriguez, J. M., Miranda, D., Bunout, D. C., Ronco, A. M., de la Maza, M. P., & Hirsch, S. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1011285 · Cited by 10
21st Century Cures Act and similar policy efforts: at what cost?:
Zuckerman, D. M., Jury, N. J., & Silcox, C. (2015) · BMJ · doi:10.1136/bmj.h6122 · Cited by 10
APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
Sjödin, S., Andersson, K., Mercken, M. H., Zetterberg, H., Borghys, H., Blennow, K., & Portelius, E. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0160-z · Cited by 10
“However, recent clinical trials where AD patients were treated with γ-secretase inhibitors failed to reach their primary clinical endpoints; the cognitive decline was even worse in the treatment arm than in placebo [13, 14].”
ResultNuovo, G. J., Paniccia, B., Mezache, L., Quiñónez, M., Williams, J. M., Vandiver, P., Fadda, P., & Amann, V. (2017) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2017.02.006 · Cited by 10
Nash, A., Gijsen, H. J. M., Hrupka, B. J., Teng, K. S.-L., Lichtenthaler, S. F., Takeshima, H., Gunnersen, J. M., & Munro, K. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94369-0 · Cited by 11
Liu, Y., Cong, L., Han, C., Li, B., & Dai, R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666201127104539 · Cited by 11
Schultz, S. A., Shirzadi, Z., Schultz, A. P., Liu, L., Fitzpatrick, C. D., McDade, E., Barthélemy, N. R., Renton, A. E., Esposito, B. T., Joseph‐Mathurin, N., et al. (2023) · Aging Cell · doi:10.1111/acel.13871 · Cited by 10
“However, reductions in β- amyloid burden are not necessarily accompanied by corresponding improvements in rates of cognitive and functional decline (Doody et al., 2013; Henley et al., 2019; Honig et al., 2018; Salloway et al., 2021; Sevigny et al., 2016).”
BackgroundSelf-citationChanges in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease
Rosenberg, P. B., Lanctôt, K. L., Herrmann, N., Mintzer, J. E., Porsteinsson, A. P., Sun, X., & Raman, R. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151113 · Cited by 13
“There were no significant differences between clinical characteristics of groups assigned to placebo, semagacestat 100 mg, or semagacestat 140 mg daily as previously reported [12].”
BackgroundMethodSelf-citationAlternative Approaches to the Search for Alzheimer’s Disease Treatments
Lien, E. J. C., Adams, J. D., Jr., Lien, L. L.-M., & Law, M. (2018) · J — Multidisciplinary Scientific Journal · doi:10.3390/j1010002 · Cited by 10
Wang, X.-B., Ding, D., Zhao, Q.-H., Liang, X.-N., Peng, L., Zhao, X., Xi, Q., Min, Z., Wang, W., Xu, X.-W., et al. (2020) · Aging · doi:10.18632/aging.102888 · Cited by 8
Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Nie, P., Kalidindi, T., Nagle, V. L., Wu, X., Li, T., Liao, G. P., Frost, G., Henry, K. E., Punzalan, B., Carter, L. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0940 · Cited by 10
“In this study, we have developed a novel PET probe (PN67) based on the scaffold of Semagacestat, the first GSI that was taken into phase III trials (14).”
MethodQuerfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
“(Semagacestat) [1] and BACE (Verubecestat) [2] inhibitors and passive immunotherapies (Bapineuzumab, Gantenerumab, Solanezumab, IVIG) [3–6].”
BackgroundAPP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ
Luo, M., Zhou, J., Sun, C., Chen, W., Fu, C., Si, C., Zhang, Y., Geng, Y., & Chen, Y. (2024) · eLife · doi:10.7554/elife.100968.3 · Cited by 9
Devkota, S., Maesako, M., & Wolfe, M. S. (2025) · Biomolecules · doi:10.3390/biom15070955 · Cited by 9
“Indeed, γ -secretase inhibitors caused cognitive worsening in advanced clinical trials [18,19].”
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 10
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Cognitive decline in diabetic mice predisposed to Alzheimer’s disease is greater than in wild type
Carús-Cadavieco, M., Berenguer, I., Canelo, A. M., Serrano-Lope, M. A., la Fuente, S. G., Aguado, B., Fernández‐Rodrigo, A., Saido, T. C., Frank, A., Venero, C., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202201789 · Cited by 9
“…is required to preserve cognitive function does appear to apply also in humans, because two large phase 3 clinical trials with the γ-secretase inhibitor Semagacestat were prematurely interrupted because of the observation of detrimental effects on cognition and functionality (Doody et al, 2013).”
BackgroundTriumbari, E. K. A., Chiaravalloti, A., Schillaci, O., Mercuri, N. B., & Liguori, C. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240349 · Cited by 9
Therapeutic agents for Alzheimer’s disease: a critical appraisal
Weinstock, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1484615 · Cited by 10
“However, a phase 3 trial in patients with mild to moderate AD was prematurely stopped because the drug actually worsened several measures of cognitive function (Doody et al., 2013).”
Roher, A. E., Maarouf, C. L., Kokjohn, T. A., Whiteside, C. M., Kalback, W. M., Serrano, G. E., Belden, C. M., Liebsack, C., Jacobson, S. A., Sabbagh, M. N., et al. (2014) · Europe PMC (PubMed Central) · Cited by 15
Mitani, Y., Akashiba, H., Saita, K., Yarimizu, J., Uchino, H., Okabe, M., Asai, M., Yamasaki, S., Nozawa, T., Ishikawa, N., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.12.013 · Cited by 10
“, 2012), which may be relevant to the fact that both GSIs worsened cognition scores in AD patients (Coric et al., 2012; Doody et al., 2013).”
BackgroundInfluentialPerspectives on the discovery of NOTCH2‐specific inhibitors
Dobranowski, P., Ban, F., Contreras‐Sanz, A., Cherkasov, A. R., & Black, P. C. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13132 · Cited by 10
Alzheimer’s disease and its current treatments; Is there a possibility for a cure?
Hathout, R. M., Ammar, E., Mohamed, I., Marel, M., Mohamed, A. S., Nourhan, Z., Abdelbaset, O., Sara, A., Mayar, M., Mirna, M., et al. (2019) · Open Journal of Chemistry · doi:10.17352/ojc.000012 · Cited by 9
Isla, A. G., Balleza‐Tapia, H., & Fisahn, A. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113743 · Cited by 9
“This action could explain the failure of this particular drug during its phase 3 clinical trial (Doody et al., 2013).”
BackgroundHouser, M. C., Turchyna, Y., Perrin, F., Chibnik, L. B., Berezovska, O., & Maesako, M. (2021) · Biosensors · doi:10.3390/bios11060169 · Cited by 13
“However, prevention of proper Notch1 cleavage and subsequent disruption of the intracellular signaling resulted in undesired adverse events such as skin cancer [14].”
BackgroundYuan, S., Yin, Y., Wang, K., Zhou, H., & Qian, C. (2022) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0114 · Cited by 9
A Novel Small Molecule Modulator of Amyloid Pathology
Lovell, M. A., Lynn, B. C., Fister, S. X., Bradley‐Whitman, M. A., Murphy, M. P., Beckett, T. L., & Norris, C. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151160 · Cited by 9
Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease
Musiek, E. S., McDade, E., & Holtzman, D. M. (2023) · Annals of Neurology · doi:10.1002/ana.26643 · Cited by 9
Alzheimer’s Disease and Dementia
Lewis, P. A., & Spillane, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811069-0.00002-1 · Cited by 11
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Shaw, C. A. (2017) · Wiley eBooks · doi:10.1002/9781118634523.refs · Cited by 9
C99 selectively accumulates in vulnerable neurons in Alzheimer’s disease
Pulina, M. V., Hopkins, M., Haroutunian, V., Greengard, P., & Bustos, V. (2019) · doi:10.1101/527572 · Cited by 9
“Semagacestat, a gamma-secretase inhibitor, worsened the symptoms of dementia in a large phase III clinical trial [29].”
Patwekar, M., Patwekar, F., Khan, S. M., Sharma, R., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266295495240415114919 · Cited by 9
Targeting the awry Aβ pathway in Alzheimer’s disease: hype and hurdles
Al-Kuraishy, H. M., Sulaiman, G. M., Al-Gareeb, A. I., Mohammed, H. A., Albuhadily, A. K., & Abomughaid, M. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01983-9 · Cited by 8
“In clinical trials, γ-secretase inhibitors semagacestat and avagacestat improve cognitive functions and reduce the production of Aβ in AD patients (Doody et al. 2013; Coric et al. 2012).”
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Huang, Q., Lv, Y. M., Ye, X. W., Xia, X., Chen, Y., Wang, X., Tong, F., Yang, W., Bozorov, K. A., Shevtsov, M. A., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114896 · Cited by 9
Chen, S., Koch, M. K., Chávez‐Gutiérrez, L., & Zacharias, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01480 · Cited by 8
Protective effect of trehalose sugar on amyloid-membrane interactions using BLM electrophysiology
Xu, Y., Filice, C. T., & Leonenko, Z. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.05.012 · Cited by 9
Li, S., & Bhalla, R. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04178-w · Cited by 8
Electrophysiological insights into Alzheimer's disease: A review of human and animal studies
Calvin, K., McNeela, A. M., Osse, A. M. L., Bhasin, G., Ridenour, M., Kinney, J. W., & Hyman, J. M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105987 · Cited by 8
Siemers, E., Feaster, T., Sethuraman, G., Sundell, K. L., Skljarevski, V., Cline, E. N., Zhang, H., Jerecìć, J., Honig, L. S., Salloway, S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100005 · Cited by 8
“Beta and gamma secretase inhibitors did not slow disease progression in clinical trials and variably showed evidence of slight worsening, likely reversible, of cognition [ 6–10 ].”
Self-citationChern, H., Caruso, G., Desaire, H., & Jarošová, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00596 · Cited by 10
Xu, Y., McRae, D. M., & Leonenko, Z. (2025) · ACS Omega · doi:10.1021/acsomega.4c07038 · Cited by 8
Larner, A. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7249-3 · Cited by 8
Brief overview of selected approaches in targeting pancreatic adenocarcinoma
Samore, W. R., & Gondi, C. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.902933 · Cited by 9
Drug Development for Neurodegenerative Diseases
Nagai, Y., & Minakawa, E. N. (2015) · Springer eBooks · doi:10.1007/978-4-431-54541-5_9 · Cited by 10
Gao, J., Wu, P., Chi, Y., Xu, H., Zhao, Y., Song, N., & Mao, Y. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-00980-2 · Cited by 8
“1 3 unsuccessful, because the results of the trial showed that it did not improve the cognitive status, and caused a significant worsening ability of daily living [27].”
BackgroundOhshima, Y., Iwata, K., Ibi, M., Matsumoto, M., Katsuyama, M., & Yabe‐Nishimura, C. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.257 · Cited by 8
Targeting γ-secretase for familial Alzheimer’s disease
Wolfe, M. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02744-3 · Cited by 8
Zhu, L., Zhang, M., Jing, H., Zhang, X.-P., Xu, L., Ma, R., Huang, F., & Shi, L. (2022) · Chinese Journal of Polymer Science · doi:10.1007/s10118-022-2799-9 · Cited by 8
Misfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 10
Lessard, C. B., Rodriguez, E., Ladd, T. B., Minter, L. M., Osborne, B. A., Miele, L., Golde, T. E., & Ran, Y. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00622-5 · Cited by 10
Anti-Amyloid Drugs for Alzheimer’s Disease: Considering the Role of Depression
Moyano, B. P., Zullo, L., Rouaud, O., Vandel, P., von Gunten, A., & Allali, G. (2024) · Neurodegenerative Diseases · doi:10.1159/000541783 · Cited by 7
“Only a few of them include a change in neuropsychiatric symptoms as a secondary outcome and some of them report depression or depressive symptoms as side effects [20 – 29] (shown in Table 1).”
Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations
Varte, V., Ralte, L., & Kumar, N. S. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00203-y · Cited by 7
“…APH-1105 is presently being used in a phase 2 study in mild-to-moderate AD (NCT03806478) [101]. γ-secretase γ-secretase inhibitors including avagacestat and semagacestat, were intended to lower Aβ42 levels, but they were constrained by side effects, primarily on Notch signaling [102] (Fig.”
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action
Nowell, J., Crook, H., de Leon, M. J., & Edison, P. (2026) · BMJ · doi:10.1136/bmj-2023-078881 · Cited by 8
Stratifying risk of Alzheimer’s disease in healthy middle-aged individuals with machine learning
Tandon, R., Zhao, L., Watson, C. M., Sarkar, N., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf121 · Cited by 7
Turton, S. M., Padgett, S., Jessup, M. T., Johnson, C. E., Buzinova, V. A., Barth, S. E., Köhler, K., Spearman, H. M., Macheda, T., Manauis, E. C., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167840 · Cited by 8
Development of CBAP-BPyne, a probe for γ-secretase and presenilinase
Gertsik, N., Ballard, T. E., Ende, C. W. A., Johnson, D. S., & Li, Y. (2014) · MedChemComm · doi:10.1039/c3md00281k · Cited by 8
Drug Targets and Biomarker Identification from Computational Study of Human Notch Signaling Pathway
Sarkar, R. R. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000137 · Cited by 7
“Recently developed several GAMMA SECRETASE inhibitors were also found to have several toxic effects [33,34].”
BackgroundAssociation between amyloid-β42 levels and neuropsychiatric symptoms in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf089 · Cited by 7
Aβ regulation-based multitarget strategy for drug discovery against Alzheimer’s disease
Guo, X., Jiang, W., Li, C., Zhu, Z., & Shen, X. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0064 · Cited by 7
“, 2013) and were in Phase III clinical trials (Doody et al., 2013).”
Twenty Years of Presenilins—Important Proteins in Health and Disease
Walter, J. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00163 · Cited by 9
Amyloid β Hypothesis in the Development of Therapeutic Agents for Alzheimer’s Disease
Adeniji, A. O., Adams, P. W., & Mody, V. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00007-6 · Cited by 13
Ioppolo, A., Eccles, M. K., Groth, D. M., Verdile, G., & Agostino, M. (2021) · Molecules · doi:10.3390/molecules27010176 · Cited by 7
“Numerous GSIs, including avagacestat and semagacestat [14,15], have progressed to clinical trials; however, they have shown off-target effects, including worsening in cognition, the development of cancers, subcutaneous tissue disorders, and gastrointestinal problems [15,16].”
BackgroundChau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2017) · Mental health and illness worldwide · doi:10.1007/978-981-10-2414-6_20 · Cited by 7
Quoi de neuf en dermatologie clinique ?
Janier, M. (2013) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(13)70140-6 · Cited by 7
The potential of signal peptide peptidase as a therapeutic target for hepatitis C
Moriishi, K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1369959 · Cited by 7
“phase III studies because of significant side effects including hematological and gastrointestinal disorders, skin reactions, increased risk of skin cancer, and hair color change [120,121].”
BackgroundHu, Y., Fang, K.-H., Shen, L., Cao, S.-Y., Yuan, F., Su, Y., Xu, M., Pan, Y., Chen, Y., & Liu, Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.809889 · Cited by 8
“In clinical trials, the severe side effect of GSI treatment was the worsening the memory in patients (22).”
BackgroundImmunotherapeutic and pharmacological approaches for the treatment of Alzheimer’s disease
Moraes, M. U., & Gaudet, T. J. (2018) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzy001 · Cited by 8
“…III trials of the first AD candidate γsecretase inhibitor, semagacestat, were aborted due to unforeseen toxicity, with serious adverse effects including susceptibility to skin cancer and infections due to decreased immunity being observed in patients treated with the drug (Doody et al., 2013).”
BackgroundBetter to be in The Placebo Arm for Trials of Neurological Therapies?
Kimmelman, J. (2018) · Cell Transplantation · doi:10.1177/0963689718755708 · Cited by 7
Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease riskPreprint
Alegbe, T., Harris, B., Fachal, L., Ramirez-Navarro, L., Tutert, M., Krzak, M., Ghouraba, M., Strickland, M., Ozols, M., Cohen, C. E., et al. (2025) · medRxiv · doi:10.1101/2025.06.24.25330216 · Cited by 8
“Although γ-secretase inhibitors were developed to reduce this pathogenic cleavage, their clinical use was curtailed by dose-limiting side effects such as weight loss and gastrointestinal bleeding 67,68 .”
Amyloidogenic and anti-amyloidogenic properties of presenilin 1
Bustos, V., Pulina, M. V., & Ledo, J. H. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.09.010 · Cited by 6
Structural biology of cell surface receptors implicated in Alzheimer’s disease
Hermans, S. J., Nero, T. L., Morton, C. J., Gooi, J. H., Crespi, G. A. N., Hancock, N. C., Gao, C., Ishii, K., Markulić, J., & Parker, M. W. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00903-9 · Cited by 6
Endosome and Lysosome Membrane Properties Functionally Link to γ-Secretase in Live/Intact Cells
Houser, M. C., Mitchell, S. P. C., Sinha, P., Lundin, B., Berezovska, O., & Maesako, M. (2023) · Sensors · doi:10.3390/s23052651 · Cited by 6
“γ-Secretase inhibitors unexpectedly caused cognitive worsening plausibly due to their impact on other substrates [12,13].”
BackgroundMondal, S., Vashi, Y., Ghosh, P., Kalita, P., Kumar, S., & Iyer, P. K. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00583 · Cited by 6
Xue, W., He, W., Yan, M., Zhao, H., & Pi, J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230559 · Cited by 6
Amyloid-independent pathogenesis for Alzheimer’s disease: implications for drug design
Wolfe, M. S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03261-9 · Cited by 6
“Moreover, clinical trials with γ -secretase inhibitors showed not only peripheral toxicity due to blocking cleavage of another substrate (Notch receptors) but also cognitive worsening of AD patients [31, 32].”
Gains and losses on the road to understanding Alzheimer’s disease
Konietzko, U. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14233 · Cited by 6
Kikis, E. A. (2017) · Healthcare · doi:10.3390/healthcare5030046 · Cited by 6
“Even when drugs have succeeded at partially reducing Aβ levels in the brain, they did little to mitigate the cognitive effects of AD [19].”
BackgroundFuture Treatment of Alzheimer Disease
Keskin, A. O., Durmaz, N., Uncu, G., Erzurumluoglu, E., Yıldırım, Z., Tuncer, N., & Adapınar, D. Ö. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85096 · Cited by 9
“Another passive immunotherapy agent R07105705 is an anti-tau antibody [39].”
BackgroundMolecular packing of lipid membranes and action mechanisms of membrane-active peptides
Chiou, P.-C., Hsu, W.-W., Chang, Y., & Chen, Y. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112384 · Cited by 6
Jin, N., Gureviciene, I., Atalay, A. N., Häkli, S., Ziyatdinova, S., & Tanila, H. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12291 · Cited by 6
Retrospective Bayesian Evidence of Null Effect in Two Decades of Alzheimer’s Disease Clinical Trials
Costa, T., Manuello, J., Cauda, F., & Liloia, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220942 · Cited by 6
Ferrero-Arias, J., & Turrión-Rojo, M. Á. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.006 · Cited by 6
Low-dose γ-secretase inhibition increases secretion of Aβ peptides and intracellular oligomeric Aβ
Agholme, L., Clarin, M., Gkanatsiou, E., Kettunen, P., Chebli, J., Brinkmalm, G., Blennow, K., Bergström, P., Portelius, E., & Zetterberg, H. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.10.009 · Cited by 7
“…(also called LY-450139) and avagacestat, have been developed thereafter, but the phase III trial with semagacestat and the phase II trial with avagacestat were struck by side effects (Coric et al, 2012; Imbimbo et al, 2011), and even leading to deteriorating cognition (Doody et al, 2013).”
What's New on Alzheimer's Disease? Insights From AD Mouse Models
Rey, C. C., Cattaud, V., Rampon, C., & Verret, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11400-x · Cited by 6
“However, Phase 3 of Clinical Trial 3 did not demonstrate any beneficial effects on cognition and higher doses resulted in serious side effects, including a worsening of functional abilities, skin cancer and infections (Doody et al., 2013).”
BackgroundIsolation of intramembrane proteases in membrane-like environments
Barniol‐Xicota, M., & Verhelst, S. H. L. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183193 · Cited by 6
Breathing new life into the rational design of Alzheimer’s therapeutics
Dries, D. R., & Yu, G. (2021) · Cell · doi:10.1016/j.cell.2026.07.046 · Cited by 6
Oxidative Stress in Neurodegenerative Diseases
Alami, M., Fülöp, T., Boumezough, K., Khalil, A., Zerif, E., & Berrougui, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-69962-7_4 · Cited by 8
Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch
Zhang, T., & Armstrong, A. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1613 · Cited by 6
Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia
Fink, H. A., Hemmy, L. S., Linskens, E. J., Silverman, P. C., MacDonald, R. H., McCarten, J. R., Talley, K. M., Desai, P. J., Forte, M. L., Miller, M. A., et al. (2020) · doi:10.23970/ahrqepccer223 · Cited by 7
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.